We recently compiled a list of the 10 Firms Drop on Bearish Statements, Disappointing Earnings. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other stocks.

Ten companies—mostly under the quantum computing sector—kicked off the trading week leading declines amid not-so-optimistic statements from chief executives and disappointing earnings updates that have weighed in on investor sentiment.

Meanwhile, Wall Street's main indices ended mixed, with the Dow Jones and S&P’s main index the only gainers, up 0.86 percent and 0.16 percent, respectively. Meanwhile, the Nasdaq Composite dropped by 0.38 percent.

To come up with Monday’s top losers, we considered only the stocks with at least $2 billion in market capitalization and $5 million in daily trading volume.

A scientist surrounded by vials and beakers in a modern laboratory, proudly displaying a vaccine.

Moderna, Inc. (NASDAQ:MRNA)

Moderna, Inc. (NASDAQ:MRNA) fell the largest on Monday, slashing 16.8 percent to close at $35.15 each after projecting a steep decline in its 2025 revenues to between $1.5 billion to $2.5 billion as compared with $3.1 billion in 2024 and $19 billion at the peak of the Covid-19 pandemic.

The lower earnings projection came on the heels of lower vaccine demand for COVID-19 vaccines and slow adoption of its respiratory syncytial virus (RSV) shot, forcing Moderna to cut costs.

Moderna (NASDAQ:MRNA) CEO Stéphane Bancel said that the vaccine maker aims to reduce 2025 cash costs by $1 billion with a plan for an additional $500 million in 2026. It expects to end 2025 with cash and investments of about $6 billion.

The company is also betting on new products to help accelerate growth. It has filed an application with the US FDA for the approval of its combination vaccine to protect against COVID-19 and influenza.

Overall MRNA ranks 1st on our list of Monday's top losers. While we acknowledge the potential of MRNA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRNA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

 

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock

 

Disclosure: None. This article is originally published at Insider Monkey.